MedTrace Logo

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT05305547 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2093

Last updated 2025-09-16

No results posted yet for this study

Summary

The main aim of this study is to evaluate the efficacy of S-217622 versus placebo among outpatient adults with mild and moderate COVID-19 starting intervention within 3 days of symptom onset.

Conditions

Interventions

DRUG

S-217622

Administered as a round tablet.

DRUG

Placebo

Administered as a round tablet.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Shionogi

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-03
Primary Completion
2024-01-07
Completion
2024-05-24
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Colombia
  • Ghana
  • India
  • Japan
  • Kenya
  • Malawi
  • Mexico
  • Pakistan
  • Peru
  • Philippines
  • Poland
  • South Africa
  • Thailand
  • Uganda

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305547 on ClinicalTrials.gov